Hearing aids effectively combat seniors' loneliness, study says
Hearing aids appear to be an effective method of countering an epidemic of loneliness among U.S. seniors, a new study says.
Seniors given hearing aids retained more friends than others who weren't provided the devices, researchers reported Monday in JAMA Internal Medicine.
Folks with hearing aids retained an average of one additional person in their social network over three years, compared to a group only provided tips on healthy aging, researchers report.
"These results support efforts to incorporate hearing aid coverage into Medicare as a means of addressing the nation's social isolation epidemic, which is especially risky for the elderly," said co-principal investigator Dr. Josef Coresh, a professor of population health at NYU Langone Health in New York City.
"Making sure Americans can continue engaging with their family and friends as they age is a critical part of maintaining their quality of life," Coresh added in a news release.
More than a quarter of seniors say they have little to no contact with others, and a third report feeling lonely, researchers said in background notes.
In 2023, then-U.S. Surgeon General Dr. Vivek Murthy issued a report warning of an epidemic of loneliness and isolation in America that has contributed to health problems like tobacco use, obesity and addiction, researchers said.
Loneliness and hearing loss also have been linked to depression, heart disease, cognitive decline and early death, researchers said.
Two-thirds of seniors 70 and older suffer from hearing loss, researchers noted. Hearing plays a vital role in communication and social connection, and people who are hard of hearing might struggle to maintain relationships.
For the clinical trial, researchers tracked nearly 1,000 men and women with hearing loss in Maryland, North Carolina, Minnesota and Mississippi.
Half of the participants ages 70 through 84 were provided hearing aids, as well as counseling sessions and personalized instruction from an audiologist. When necessary, they also were provided tools like adaptors that connect hearing aids to televisions.
The other half were given advice on healthy aging such as exercise tips and strategies for communicating with health care providers, but no hearing aids or hearing assistance, the study says.
Researchers measured the participants' social isolation by tracking how regularly they spent time with others and assessing the size and variety of their social networks.
Before the study, participants in both groups reported feeling equally lonely, researchers said.
Three years later, loneliness scores had improved slightly among those who'd received hearing aids, but slightly worsened among those who hadn't, results show.
"Our findings add to evidence that helping aging patients hear better can also enrich their social lives and boost their mental and physical well-being," lead researcher Nicholas Reed, an audiologist with the NYU Grossman School of Medicine's Optimal Aging Institute, said in a news release.
Hearing aids and audiology appointments cost an average $4,700, which is usually paid out of pocket, Coresh noted.
Researchers plan to continue following the participants for another three years, and to repeat the clinical trial in a more diverse group of patients, Coresh said.
Coresh noted that participants received hearing care that was more responsive to patients' needs than is typically offered to the public. For example, damaged hearing aids were replaced within days rather than weeks.
More information
The Hearing Loss Association of America has more on social strategies for hearing loss.
Copyright © 2025 HealthDay. All rights reserved.
Copyright 2025 UPI News Corporation. All Rights Reserved.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
30 minutes ago
- CNBC
Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs
Eli Lilly on Thursday said it is raising the list price of its blockbuster diabetes drug Mounjaro in the U.K. starting in September, as President Donald Trump pressures drugmakers to lower U.S. drug prices and hike them abroad. In a statement, Eli Lilly said it reached an agreement with the U.K. government to increase the list price of the weekly injection, while "maintaining access" for patients covered under the publicly funded health-care system, the National Health Service, or NHS. Eli Lilly told CNBC that the price hike will not affect the drug's availability under NHS, and it wants to work with the government to boost access. The company added that it does not determine prices that private health-care providers set, but is working with them to ensure access to Mounjaro. In a statement on Thursday, NHS said Mounjaro's list price increase "will not affect NHS commissioning of tirzepatide in England for eligible people living with obesity, based on clinical priority, or as a treatment for type 2 diabetes." Tirzepatide is the active ingredient in Mounjaro and its counterpart for weight loss, Zepbound. Mounjaro's current list price in the UK ranges from £92 (about $124.89) to £122 a month, depending on the dose size, according to Eli Lilly. The drug's new list price will increase to between £133 and £330 starting on Sept. 1. The company added that it is working with certain governments and expects to make pricing adjustments in those countries by that date. In the U.S., the list price for a month's supply of Mounjaro is $1,079.77 before insurance and other rebates. Eli Lilly said it supports the Trump administration's goal of keeping the U.S. the "world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries." "This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US," the company said in the statement. The announcement comes after Trump in July sent separate letters to 17 drugmakers, including Eli Lilly, calling on them to take steps to lower drug prices by Sept. 29. The move built on the president's executive order in May reviving a controversial plan – the "most favored nation" policy – that aims to slash drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad. U.S. prescription drug prices are two-to-three times higher on average than those in other developed nations – and up to 10 times more than in certain countries, according to the Rand Corp., a public policy think tank. Trump has said he wants to narrow that gap to stop Americans from being "ripped off." Eli Lilly's announcement on Thursday comes as the industry braces for Trump's planned tariffs on pharmaceuticals imported into the U.S. In its statement, the company said it opposes those tariffs, arguing they will "raise costs, limit patient access, and undermine American leadership, especially for companies already investing heavily in domestic manufacturing." In recent months, Eli Lilly was among several drugmakers to announce new plans to invest in U.S. manufacturing sites.
Yahoo
33 minutes ago
- Yahoo
Eli Lilly hikes UK price of blockbuster weight loss drug Mounjaro by up to 170%
Drugmaker Eli Lilly said it will raise the price of its blockbuster weight loss drug by up to 170 per cent for customers in the United Kingdom. The US pharmaceutical giant confirmed to Euronews Health that effective September 1, the highest dose of Mounjaro will cost £330 for a month's supply, up from £122 currently. The new price is the list price, or what private providers will pay for the drug. Clinics are expected to raise their prices for patients as a result. The price hike is not expected to affect access for patients who receive Mounjaro through the National Health Service (NHS), a spokesperson for NHS England said. 'The approved list price increase will not affect NHS commissioning of [Mounjaro] in England for eligible people living with obesity, based on clinical priority, or as a treatment for type 2 diabetes,' the spokesperson told Euronews Health. Related Eli Lilly will seek approval for experimental weight loss pill after promising study The NHS England spokesperson said patients who get the drug through private doctors should contact their providers. A Lilly spokesperson said the company will work with private doctors to "maintain patient access'. Mounjaro is used to treat obesity, type 2 diabetes, and weight-related health problems in both the UK and the European Union. Rival weight loss jabs Ozempic and Wegovy, made by Danish drugmaker Novo Nordisk, are also available. A Lilly spokesperson said the increase aims to bring Mounjaro's UK price closer to what is paid in other European countries. 'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability,' the spokesperson said. 'With changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation'. The move comes as US President Donald Trump puts pressure on pharmaceutical companies to lower drug costs for Americans to a level that matches the lowest price offered in other wealthy countries. Related Portugal tightens rules on weight loss drug prescriptions to prevent misuse In May, Trump complained that a 'friend' of his paid significantly less for 'the fat shot' in the UK than in the United States. He later accused European countries of 'freeloading,' saying Americans pay higher prices to cover the cost of new drug development while other wealthy countries benefit. Since then, some drug companies have signaled they will attempt to align prices paid in the US and other countries. The Lilly spokesperson said the Mounjaro price increase will 'address pricing inconsistencies compared to other developed countries, including in Europe'.
Yahoo
an hour ago
- Yahoo
'Legally binding' dye agreement with WK Kellogg lauded by Texas attorney general
WK Kellogg has entered a legally binding agreement to remove 'toxic dyes' from its breakfast cereals, according to Texas Attorney General Ken Paxton. Paxton said in a statement shared by his office yesterday (13 August) that he has 'signed a historic Assurance of Voluntary Compliance' agreement with WK Kellogg, which, he added, 'certifies that the company is legally agreeing to remove artificial food colourings from its cereals by the end of 2027'. Under a transparency commitment on the WK Kellogg website, the company says 85% of its cereals contain no FD&C colours and none contain the Red No. 3 dye. Reformulations to remove all FD&C colours in cereals served in schools will be completed by 2026-27, the company says, adding: 'We will remove FD&C colours from the small percentage of our foods in retail that contain them' by the end of 2027. However, the pledges are not legally binding. Just Food has asked WK Kellogg to comment on the Paxton statement. WK Kellogg responded, repeating the pledges made in the online transparency commitment. However, the company added: 'We appreciate the opportunity to work collaboratively with the Texas AG's office and share their focus on health and wellness. We see the growing focus on health as an opportunity to meet consumer needs in even more meaningful ways.' The attorney general launched an investigation in April into WK Kellogg's claims that its cereals are 'healthy'. Paxton had suggested the products 'are filled with petroleum-based artificial food colourings' that have been linked to health issues such as hyperactivity, obesity, autoimmune disorders, hormonal imbalances, and cancer. And he claimed some of WK Kellogg's products 'specifically contain' artificial food dyes in shades of blue, red, yellow, green and orange. Yesterday, Paxton lauded the development with WK Kellogg as a 'historic legal agreement with a major food company', which, he said, 'represents a significant milestone in the movement to remove toxic dyes from foods and protect the health of all Americans'. He added: 'While other companies have verbally committed to removing food dyes, Kellogg's is the first to officially sign a legally binding agreement confirming that it will remove food colourings.' Since President Trump took office, US Health Secretary Robert F. Kennedy Jr. has launched a campaign – under his Make America Healthy Again (MAHA) initiative - to urge major food manufacturers to phase out the use of artificial dyes. Many have since made pledges to do that but under their own auspices, including Kraft Heinz and General Mills. In January, the US Food and Drug Administration (FDA) said it planned to ban the use of the Red 3 food colouring additive in food, supplements and ingestible drugs. Then in April, the FDA unveiled measures to phase out the use of petroleum-based food dyes by the end of next year, followed by the approval in May for the use of three natural colour additives. Paxton applauded WK Kellogg 'for doing the right thing' and urged 'other food manufacturers to sign similar agreements to demonstrate their commitment to helping Americans live healthier lives'. Meanwhile, markets await news of the progress in Ferrero's takeover of WK Kellogg. The confectionery giant entered an agreement in July to acquire the business for $3.1bn, with the deal expected to close in the current second half of this year. However, it needs to be signed off by regulators and WK Kellogg's shareholders. "'Legally binding' dye agreement with WK Kellogg lauded by Texas attorney general" was originally created and published by Just Food, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
